New First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia[1]
NIKTIMVO® (axatilimab) approved by the Therapeutic Goods Administration (TGA) under Priority Review for the treatment of eligible Australian patients with chronic graft-versus-host disease[2] Australia becomes the first country to obtain Marketing …